|

A Randomized Controlled Study of the NEURESCUE Device as an Adjunct to Advanced Cardiac Life Support

RECRUITINGN/ASponsored by neurescue
Actively Recruiting
PhaseN/A
Sponsorneurescue
Started2025-07-07
Est. completion2027-01
Eligibility
Age18 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06793033

Summary

The NEURESCUE device is the first intelligent balloon catheter for aortic balloon occlusion (ABO), an emergency technique that supercharges blood flow to the heart and brain within one minute from deployment. The catheter-based device is delivered via the femoral artery, temporarily inflating a soft balloon in the descending to redirect blood flow towards the upper body. The purpose of this study is to compare the clinical safety and performance of Advanced Cardiovascular Life Support (ACLS) versus ACLS in combination with Aortic Balloon Occlusion (ABO) using the NEURESCUE device in subjects with cardiac arrest.

Eligibility

Age: 18 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

* Age ≥18 and ≤80 years
* Witnessed arrest
* CPR initiated within 7 min of arrest
* CPR time less than 40 min at enrollment
* Non-shockable rhythm

Exclusion Criteria:

* Traumatic cardiac arrest
* Known pregnancy
* Known terminal disease
* Known do-not-attempt-CPR order
* Known opposition to study participation

Conditions3

Cardiac Arrest (CA)Cardiopulmonary ArrestHeart Disease

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.